Results for this period
Full year1 April 2025–31 March 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue declined substantially because overseas revenue recorded in the previous fiscal year was not recorded this year. Together with the increase in selling, general and administrative expenses, including personnel and research and development expenses, this caused operating, ordinary and net losses to widen.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥323 million (YoY -66.4%) |
| Operating profit | ¥-748 million |
| Ordinary income | ¥-778 million |
| Profit attributable to owners of the parent | ¥-780 million |
| Net income per share | -¥22.95 |
| Operating Margin | △231.6％ |
| Equity ratio | End of the current fiscal period 54.1％ / End of previous period 59.2％ |
| Total assets | ¥4,486 million |
| Net assets | ¥2,426 million |
| Cash flows from operating activities | ¥-334 million |
| Cash flows from investing activities | ¥-15 million |
| Cash flows from financing activities | ¥-33 million |
| Cash and cash equivalents at end of period | ¥2,778 million |
| Full-year earnings forecast | Net Sales ¥1,038 million (YoY +221.0%) / Operating profit ¥-696 million / Ordinary income ¥-625 million / Net income ¥-628 million |
| Annual Dividend Forecast | ¥0.00 → ¥0.00 |
| Depreciation and amortization | ¥28,600 thousand |
| Breakdown of extraordinary income (loss) | No applicable matters |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Material subsequent events | On 16 April 2026, payment for and allotment of 1,000,000 common shares and 10,500 fifth series stock acquisition rights through a third-party allotment were completed. The funds raised are予定 to be allocated to clinical trials targeting rare cancers, research and development, overseas expansion, and the establishment of a stable supply system. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 34,034,100 shares |
| Treasury Shares at Period-End | 14,107 shares |
| Factors Behind Changes in Business Performance | Revenue declined substantially because overseas revenue recorded in the previous fiscal year was not recorded this year. Together with the increase in selling, general and administrative expenses, including personnel and research and development expenses, this caused operating, ordinary and net losses to widen. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In addition to the absence of overseas revenue recorded in the previous fiscal year, selling, general and administrative expenses, including personnel and research and development expenses, increased.